Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology’s Q2 2026 earnings call highlighted revenue growth driven entirely by NERLYNX. Total revenue rose to $56.5 million from $52.4 million in Q2 2025, while net product revenue increased to $53.6 million, matching NERLYNX sales of 2,930 bottles ex-factory. Royalty revenue was $2.9 million versus $3.2 million a year earlier. GAAP net income increased to $8.2 million (or $0.16 diluted) and non-GAAP net income to $10.1 million (or $0.19). The company raised full-year net product revenue guidance to $205 million–$209 million and net income to $17 million–$20 million, while lowering royalty guidance to $19 million–$22 million. Cash totaled $93.9 million as of June 30, 2026.